Device Firms Eye Rocketing Pay-For-Performance Insurance Plans Warily
This article was originally published in The Gray Sheet
Industry group AdvaMed says it is concerned a rapid shift toward pay-for performance and financial risk-sharing models by commercial insurers will discourage providers from giving patients newer devices and could stifle innovation.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.